Currently we test and support the following browsers:
Please note that this is not intended to be an exhaustive list of browsers that support web standards, nor a test of browser compliance, nor a side-by-side comparison of various manufacturers’ browsers.
Infectious Diseases : adenovirus
The purpose of this study is to determine whether Brincidofovir (or BCV for short) is a safe and effective treatment for adenovirus. BCVis being made available through this study as an experimental option for the treatment of adenovirus infection.
BCV is a modified form of an approved antiviral drug called cidofovir (or Vistide). BCV is taken by mouth and converted into cidofovir inside the body. Cidofovir isused for the treatment of adenovirus. Cidofovir works by blocking the virus from multiplying inside the body. However, cidofovir is very toxic to kidneys. Although BCV is converted to cidofovir inside the body, since BCV is a different form of cidofovir, it may be less toxic to kidneys, although this cannot be guaranteed.
For the current eligibility status of this clinical study, referring physicians must contact St. Jude Children's Research Hospital at 1-866-2ST-JUDE (1-866-278-5833).
Gabriela Marón, MD
St. Jude Children’s Research Hospital
262 Danny Thomas Place
Memphis, TN 38105 USA
Voice: 1-888-226-4343 or 901-595-4055
Referring or consulting physicians only: firstname.lastname@example.org
For all other inquiries about St. Jude Children's Research Hospital studies: email@example.com
The above information is intended to provide only a basic description about a research protocol that may be currently active at St. Jude. The details made available here may not be the most up-to-date information on protocols used by St. Jude. To receive full details about a protocol and its status and or use at St. Jude, a physician must contact St. Jude directly.